cangrelor

URI: https://gptkb.org/entity/cangrelor

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:drug gptkb:anticoagulant P2Y12 inhibitor
gptkbp:approvalYear	2015
gptkbp:approvedBy	gptkb:FDA gptkb:EMA
gptkbp:ATCCode	gptkb:B01AC10
gptkbp:brand	gptkb:Kengreal gptkb:Kengrexal
gptkbp:CASNumber	gptkb:163706-06-7
gptkbp:chemicalFormula	C17H25F3N5O12P3
gptkbp:contraindication	active bleeding history of hypersensitivity to cangrelor
gptkbp:developedBy	gptkb:The_Medicines_Company
gptkbp:eliminationHalfLife	3–6 minutes
gptkbp:excretion	urine feces
https://www.w3.org/2000/01/rdf-schema#label	cangrelor
gptkbp:IUPACName	(2S)-2-[[(3aS,4S,6R,6aR)-6-(6-amino-2-chloro-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl]oxy]-3,3,3-trifluoro-2-hydroxypropyl]phosphonic acid
gptkbp:KEGGID	D09913
gptkbp:legalStatus	prescription only
gptkbp:mechanismOfAction	reversible P2Y12 receptor antagonist
gptkbp:metabolism	dephosphorylation
gptkbp:molecularWeight	774.33 g/mol
gptkbp:pregnancyCategory	gptkb:B3 not assigned
gptkbp:proteinBinding	97–98%
gptkbp:PubChem_CID	gptkb:CHEMBL1201837 148192 130574 DB06448
gptkbp:routeOfAdministration	intravenous
gptkbp:sideEffect	bleeding dyspnea hypersensitivity reactions
gptkbp:synonym	gptkb:Cangrelor_tetrasodium gptkb:AR-C69931MX
gptkbp:UNII	K89E2J6C0B
gptkbp:usedFor	reducing risk of periprocedural thrombotic events patients undergoing percutaneous coronary intervention
gptkbp:bfsParent	gptkb:AR-C
gptkbp:bfsLayer	6